Go Pro
→ Your book is inside (From Profits Run) (Ad)tc pixel Free NCYT Stock Alerts

Novacyt (NCYT) Competitors

Novacyt logo
GBX 35 +0.50 (+1.45%)
As of 07/13/2026 11:53 AM Eastern
Compare

NCYT vs. CREO, IUG, IHC, RUA, and AVO

Should you buy Novacyt stock or one of its competitors? MarketBeat compares Novacyt with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novacyt include Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Inspiration Healthcare Group (IHC), RUA Life Sciences (RUA), and Advanced Oncotherapy (AVO). These companies are all part of the "medical devices" industry.

How does Novacyt compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Creo Medical Group had 3 more articles in the media than Novacyt. MarketBeat recorded 3 mentions for Creo Medical Group and 0 mentions for Novacyt. Creo Medical Group's average media sentiment score of 1.27 beat Novacyt's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Creo Medical Group Positive
Novacyt Neutral

Creo Medical Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M11.54-£25.04M£1.0014.25
Novacyt£20.03M1.27-£36.80M-£32.00N/A

Creo Medical Group has a beta of 1.6212822, indicating that its share price is 62% more volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, indicating that its share price is 11% more volatile than the broader market.

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 6.9% of Creo Medical Group shares are owned by insiders. Comparatively, 0.4% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Creo Medical Group has a net margin of 88.33% compared to Novacyt's net margin of -103.08%. Creo Medical Group's return on equity of 9.56% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Novacyt -103.08%-96.44%-27.98%

Summary

Creo Medical Group beats Novacyt on 12 of the 13 factors compared between the two stocks.

How does Novacyt compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Intelligent Ultrasound Group has a net margin of -23.11% compared to Novacyt's net margin of -103.08%. Intelligent Ultrasound Group's return on equity of -23.58% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
Novacyt -103.08%-96.44%-27.98%

Intelligent Ultrasound Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
Novacyt£20.03M1.27-£36.80M-£32.00N/A

Intelligent Ultrasound Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, indicating that its stock price is 11% more volatile than the broader market.

75.5% of Intelligent Ultrasound Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 12.8% of Intelligent Ultrasound Group shares are held by insiders. Comparatively, 0.4% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Intelligent Ultrasound Group's average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
Novacyt Neutral

Summary

Intelligent Ultrasound Group beats Novacyt on 7 of the 10 factors compared between the two stocks.

How does Novacyt compare to Inspiration Healthcare Group?

Inspiration Healthcare Group (LON:IHC) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

7.4% of Inspiration Healthcare Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 6.1% of Inspiration Healthcare Group shares are held by company insiders. Comparatively, 0.4% of Novacyt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Inspiration Healthcare Group has higher revenue and earnings than Novacyt. Inspiration Healthcare Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspiration Healthcare Group£47.55M0.35-£12.20M-£1.16N/A
Novacyt£20.03M1.27-£36.80M-£32.00N/A

Inspiration Healthcare Group has a net margin of -2.19% compared to Novacyt's net margin of -103.08%. Inspiration Healthcare Group's return on equity of -6.49% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Inspiration Healthcare Group-2.19% -6.49% -3.47%
Novacyt -103.08%-96.44%-27.98%

Inspiration Healthcare Group has a beta of 0.872, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, suggesting that its stock price is 11% more volatile than the broader market.

In the previous week, Inspiration Healthcare Group's average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score.

Company Overall Sentiment
Inspiration Healthcare Group Neutral
Novacyt Neutral

Summary

Inspiration Healthcare Group beats Novacyt on 7 of the 11 factors compared between the two stocks.

How does Novacyt compare to RUA Life Sciences?

Novacyt (LON:NCYT) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

10.7% of Novacyt shares are owned by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are owned by institutional investors. 0.4% of Novacyt shares are owned by insiders. Comparatively, 7.3% of RUA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

RUA Life Sciences has lower revenue, but higher earnings than Novacyt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.27-£36.80M-£32.00N/A
RUA Life Sciences£4.11M3.70-£2.66MN/AN/A

In the previous week, Novacyt's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
Novacyt Neutral
RUA Life Sciences Neutral

Novacyt has a beta of 1.105, indicating that its stock price is 11% more volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.948, indicating that its stock price is 5% less volatile than the broader market.

RUA Life Sciences has a net margin of -3.26% compared to Novacyt's net margin of -103.08%. RUA Life Sciences' return on equity of -2.03% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-103.08% -96.44% -27.98%
RUA Life Sciences -3.26%-2.03%-17.50%

Summary

RUA Life Sciences beats Novacyt on 6 of the 10 factors compared between the two stocks.

How does Novacyt compare to Advanced Oncotherapy?

Novacyt (LON:NCYT) and Advanced Oncotherapy (LON:AVO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Advanced Oncotherapy has lower revenue, but higher earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.27-£36.80M-£32.00N/A
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A

Novacyt has a beta of 1.105, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Advanced Oncotherapy has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

In the previous week, Novacyt's average media sentiment score of 0.00 equaled Advanced Oncotherapy'saverage media sentiment score.

Company Overall Sentiment
Novacyt Neutral
Advanced Oncotherapy Neutral

10.7% of Novacyt shares are held by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are held by institutional investors. 0.4% of Novacyt shares are held by insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Advanced Oncotherapy has a net margin of 0.00% compared to Novacyt's net margin of -103.08%. Advanced Oncotherapy's return on equity of -67.34% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-103.08% -96.44% -27.98%
Advanced Oncotherapy N/A -67.34%-11.73%

Summary

Advanced Oncotherapy beats Novacyt on 7 of the 10 factors compared between the two stocks.

Get Novacyt News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCYT vs. The Competition

Export
MetricNovacytMedical Devices IndustryMedical SectorLON Exchange
Market Cap£25.36M£2.16B£7.05B£2.85B
Dividend YieldN/A2.65%2.68%6.16%
P/E Ratio-1.0914.7227.11368.18
Price / Sales1.27129.45587.9284,612.72
Price / Cash0.5815.9929.2227.87
Price / Book0.354.6310.757.49
Net Income-£36.80M£144.75M£3.58B£5.89B
7 Day Performance-1.41%0.61%-2.06%-0.19%
1 Month Performance-5.10%1.74%3.32%-1.00%
1 Year Performance-14.63%0.27%26.35%61.67%

Novacyt Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCYT
Novacyt
N/AGBX 35
+1.4%		N/A-13.1%£25.36M£20.03MN/A120
CREO
Creo Medical Group
N/AGBX 14.60
-1.0%		GBX 40
+174.0%		+10.7%£70.93M£6M14.60279
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
IHC
Inspiration Healthcare Group
N/AGBX 20
+2.6%		N/A-6.9%£17.48M£47.55MN/A224
RUA
RUA Life Sciences
N/AGBX 20.65
+5.9%		N/A+109.0%£12.82M£4.11MN/A48

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NCYT) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
Forget SpaceX, this is Elon’s Next Breakthrough
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel